A Phase II Trial of Topotecan in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

By Miller D.S.   Blessing J.A.   Lentz S.S.   Waggoner S.E.  

Gynecologic Oncology, Vol. 87, Iss. 3, 2002-12 ,pp. : 247-251

Academic Press

Access to resources Recommend Favorite

Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study

By Covens A.   Brunetto V.L.   Markman M.   Orr J.W.   Lentz S.S.   Benda J.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 470-474

Elsevier

Access to resources Recommend Favorite

Phase II Trial of Pyrazoloacridine in Patients with Persistent or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

By Plaxe S.C.   Blessing J.A.   Husseinzadeh N.   Webster K.D.   Rader J.S.   Dunton C.J.  

Gynecologic Oncology, Vol. 84, Iss. 2, 2002-02 ,pp. : 241-244

Elsevier

Access to resources Recommend Favorite

A Phase II Trial of Prolonged Oral Etoposide (VP-16) as Second-Line Therapy for Advanced and Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

By Rose P.G.   Blessing J.A.   Lewandowski G.S.   Creasman W.T.   Webster K.D.  

Gynecologic Oncology, Vol. 63, Iss. 1, 1996-10 ,pp. : 101-104

Academic Press

Access to resources Recommend Favorite

Dactinomycin in the Treatment of Recurrent or Persistent Endometrial Carcinoma: A Phase II Study of the Gynecologic Oncology Group

By Moore D.H.   Blessing J.A.   Dunton C.   Buller R.E.   Reid G.C.  

Gynecologic Oncology, Vol. 75, Iss. 3, 1999-12 ,pp. : 473-475

Elsevier

Access to resources Recommend Favorite